All In Biotech

Drug Trial Radar · NCT06909214

A Study to Evaluate the Clinical Outcomes of Efgartigimod PH20 SC in Adults With New-onset Generalized Myasthenia Gravis (gMG)

A Phase 4, Open-Label, Prospective, Single-Group, Multicenter Study to Evaluate the Clinical Outcomes of Efgartigimod PH20 SC in Adult Participants With New-Onset Generalized Myasthenia Gravis

Last checked: Nov 20, 2026Latest source record: Nov 19, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

35

Planned (sponsor's estimate)

Start

Apr 17, 2025

Primary completion

Jul 8, 2026

Study completion Dec 2027

Sponsor

Lead sponsor
argenxargenx (ARGX)
Sponsor type
Industry
First posted
Apr 3, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The main purpose of this study is to measure how well adults with new-onset gMG (which means they've had generalized disease signs and/or symptoms for less than 1 year) respond to treatment with efgartigimod PH20 SC. The study consists of a treatment period of 103 weeks (51 weeks in stage 1, 52 weeks in stage 2). The study duration for each participant will be approximately 107 weeks.

Conditions

  • New Onset Generalized Myasthenia Gravis (gMG)

Interventions

  • Efgartigimod PH20 SCBiological

    Subcutaneous injection of efgartigimod PH20 SC

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Proportion of participants who reach MSE of MG at any time within the first 16 weeks of stage 1 treatment with efgartigimod PH20 SCTime frame: up to 16 weeks

Locations

18 sites in 1 country. Site status is shown where the registry gives one.

  • University of California, San Diego - Altman Clinical and Translational Research Institute (ACTRI)

    La Jolla, California · Recruiting

  • Samir Macwan, M.D., Inc. (S corporation)

    Rancho Mirage, California · Recruiting

  • EZR Research

    Boca Raton, Florida · Recruiting

  • University of Florida Jacksonville

    Jacksonville, Florida · Recruiting

  • Visionary Investigators Network

    Miami, Florida · Recruiting

  • University of California Irvine

    Orange, Florida · Recruiting

  • Medsol Clinical Research Center Inc

    Port Charlotte, Florida · Recruiting

  • Baycare Medical Group

    St. Petersburg, Florida · Recruiting

  • Emory Brain Health Center

    Atlanta, Georgia · Recruiting

  • The Queen's Medical Center - West Oahu

    Honolulu, Hawaii · Recruiting

  • Hawaii Pacific Neuroscience

    Honolulu, Hawaii · Recruiting

  • HSHS Medical Group

    O'Fallon, Illinois · Recruiting

  • UMass Memorial Medical Center

    Worcester, Massachusetts · Recruiting

  • Henry Ford Health System

    Detroit, Michigan · Recruiting

  • Cleveland Clinic

    Cleveland, Ohio · Recruiting

  • Erlanger Neuroscience Institute

    Chattanooga, Tennessee · Recruiting

  • Central Texas Neurology Consultants - Elligo

    Round Rock, Texas · Recruiting

  • Center for Neurological Disorders - Greenfield

    Greenfield, Wisconsin · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.